Antipsychotic drugs are central to the treatment of schizophrenia and other psychotic
disorders but are ineffective for some patients and associated with side-effects and …

Schizophrenia is a chronic and debilitating neuropsychiatric disorder affecting
approximately 1% of the world's population. This disease is associated with considerable …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

Antipsychotic medications can induce cardiovascular and metabolic abnormalities (such as
obesity, hyperglycemia, dyslipidemia and the metabolic syndrome) that are associated with …

Background: Schizophrenia is among the major causes of disability worldwide and the
mortality from cardiovascular disease (CVD) is significantly elevated. There is a growing …

Originally published in February 2004. This guideline is more than 5 years old and has not
yet been updated to ensure that it reflects current knowledge and practice. In accordance …

Serotonin is perhaps best known as a neurotransmitter that modulates neural activity and a
wide range of neuropsychological processes, and drugs that target serotonin receptors are …

Polypharmacology describes the activity of compounds at multiple targets. Current research
focuses on two aspects of polypharmacology:(1) unintended polypharmacology can lead to …

Many drugs target the serotonin 2A receptor (5-HT2AR), including second-generation
antipsychotics that also target the dopamine D2 receptor (D2R). These drugs often produce …

Objective To review recent advances in the epidemiology, pathobiology, and management
of weight gain and obesity in patients with schizophrenia and to evaluate the extent to which …